GODAVARI DRUGS LTD. (GODAVARI) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of GODAVARI DRUGS LTD. stock ₹56.19, price ₹116, that is 51.5% below the price, quality 13 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
GODAVARI DRUGS LTD.
GODAVARI · BSEFar too expensive (fair value 52% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range ₹52.20 – ₹147.75 · fair‑value band ₹40.60 – ₹80.92 · the ₹115.90 price screens above the ₹56.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether GODAVARI DRUGS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Godavari Drugs Limited manufactures and supplies active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India.
Show moreShow less
It offers APIs, including ciprofloxacin HCl, ciprofloxacin lactate, ciprofloxacin betaine, mefenamic acid, enrofloxacin, and elthambutoal HCI; and intermediaries, such as A D lactone for spironolactone and 6 mercaptopurine for azathioprine.
The company also provides loan license and contract manufacturing services. It serves the life science industry. The company was incorporated in 1987 and is based in Secunderabad, India.
Stock analysis
GODAVARI DRUGS LTD. (GODAVARI) currently trades at ₹115.90, while our model-based Fair Value estimate is ₹56.19, 52% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹73.23 per share, and 0 of the 14 models we run sit above the ₹115.90 price.
Bear case: the Earnings-Based group reads lowest at ₹32.44, and 14 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹40.60 (bear) to ₹80.92 (bull), the price of ₹115.90 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 13/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
GODAVARI DRUGS LTD. reported revenue of ₹1.1B in FY2026 versus ₹1.6B in FY2022, a compound −10.0%/yr. Reported net income was ₹40.9M in FY2026, compounding −6.0%/yr from FY2022.
Key figures
Market cap ₹1.3B (≈ $13.5M) Micro · P/E ratio 22.8 · P/S ratio 1.14 · EPS (TTM) ₹5.08 · Net margin 3.7% · Return on equity 6.4% · Return on assets (EBIT) 7.0% (5-year average) · Operating margin 7.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 65% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −52%, GODAVARI screens richer than that median.
Fair Value models
All 14 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
GODAVARI screens overvalued: fair value 52% below the price. Compare with Merck KGaA →
Compare GODAVARI DRUGS LTD. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.48 | $113.53 | +36% | vs GODAVARI |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.90 | ¥52.43 | +12% | vs GODAVARI |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,872 | ₹1,983 | +6% | vs GODAVARI |
| Haleon plc HLN | $9.05 | $8.47 | −6% | vs GODAVARI |
| Merck KGaA MRK | €149.50 | €108.83 | −27% | vs GODAVARI |
| Galderma Group GALD | CHF 187.55 | CHF 112.46 | −40% | vs GODAVARI |
| Takeda Pharmaceutical Company TAK | $21.64 | $11.23 | −48% | vs GODAVARI |
| Sandoz Group SDZ | CHF 81.50 | CHF 40.91 | −50% | vs GODAVARI |
| Teva Pharmaceutical Industries Limited TEVA | $42.62 | $20.74 | −51% | vs GODAVARI |
| Divi's Laboratories Limited DIVISLAB | ₹11,049 | ₹1,567 | −86% | vs GODAVARI |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is GODAVARI DRUGS LTD. (GODAVARI) overvalued or undervalued?
What is the fair value of GODAVARI?
What is the quality score of GODAVARI?
What is the price target for GODAVARI DRUGS LTD. (GODAVARI)?
What is the GODAVARI DRUGS LTD. stock forecast for 2026?
What is the revenue of GODAVARI DRUGS LTD. (GODAVARI)?
What is the intrinsic value of GODAVARI DRUGS LTD. (GODAVARI)?
Is GODAVARI DRUGS LTD. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of GODAVARI?
How much is GODAVARI DRUGS LTD. worth?
What do the bullish and bearish scenarios say about GODAVARI?
What is the P/E ratio of GODAVARI?
How solid is the balance sheet of GODAVARI DRUGS LTD. (GODAVARI)?
How far is GODAVARI from its 52-week high?
Which stocks are comparable to GODAVARI DRUGS LTD.?
Is GODAVARI DRUGS LTD. stock attractive at the current price?
How is the fair value of GODAVARI calculated?
Is it still worth investing in stocks now?
What is the share price of GODAVARI DRUGS LTD. (GODAVARI)?
What should I pay attention to with GODAVARI DRUGS LTD. right now?
Key figures of GODAVARI DRUGS LTD.
How large is the market capitalisation of GODAVARI DRUGS LTD. (GODAVARI)?
What is the P/S ratio of GODAVARI DRUGS LTD. (GODAVARI)?
What are the earnings per share of GODAVARI DRUGS LTD. (GODAVARI)?
What is the net margin of GODAVARI DRUGS LTD. (GODAVARI)?
What is the return on equity of GODAVARI DRUGS LTD. (GODAVARI)?
What is the EBIT return on assets of GODAVARI DRUGS LTD. (GODAVARI)?
What is the operating margin of GODAVARI DRUGS LTD. (GODAVARI)?
How fast is revenue growing at GODAVARI DRUGS LTD. (GODAVARI)?
How fast are earnings growing at GODAVARI DRUGS LTD. (GODAVARI)?
How much free cash flow does GODAVARI DRUGS LTD. (GODAVARI) generate?
How much net debt does GODAVARI DRUGS LTD. (GODAVARI) carry?
Watch GODAVARI DRUGS LTD. in the live analysis
One click puts GODAVARI DRUGS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.